/ /

  • linkedin
  • Increase Font
  • Sharebar

    Visual outcomes and incidence of PCO associated with a novel IOL

    Clinical findings indicate association with low rate of PCO and good visual outcomes



    Ideally, our study would have compared the results obtained with the glistening-free lens with those of other IOLs by means of a randomised trial. Additionally, 28.7% of the eyes included in the study presented no ocular pathology, whereas 71.3% had pathology of some form including macular degeneration, glaucoma, epiretinal membrane, diabetic retinopathy and previous vitrectomy. Some of these diseases have been associated with a greater rate of posterior capsule opacification, which may have induced some selection bias.

    As mentioned previously, there is a paucity of data describing clinical outcomes following enVista IOL implantation. Nevertheless, the lens appears to compare favourably with other lenses on the market.

    Previously, we undertook a 91-patient prospective study in which patients were implanted with one of three monofocal toric IOLs: the Lentis LT (Oculentis), the enVista or the AcrySof IQ (Alcon Laboratories Inc.) or a multifocal toric IOL (the AcrySof IQ ReSTOR, Alcon Laboratories Inc.).

    Patients implanted with the glistening-free toric IOL achieved the best uncorrected distance visual acuity compared with the other monofocal IOLs, with 81% of eyes having 0.1 logMAR or better.15 Previous studies have demonstrated that the incidence of PCO following uncomplicated cataract surgery ranges from 50% to <5%;16-19 in the current study, only 5.3% of eyes required Nd:YAG laser posterior capsulotomy.

    Overall, findings from our study clearly indicate that implantation of the glistening-free IOL leads to good visual outcomes with a low incidence of PCO. These data also highlight the effect of IOL design on vision quality.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results